Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (1): 6-11.doi: 10.3969/j.issn.1000-6621.2021.01.003
• Highlight • Previous Articles Next Articles
Chinese Antituberculosis Association
Received:
2020-12-14
Online:
2021-01-10
Published:
2021-01-12
Chinese Antituberculosis Association. Tuberculosis research progress in 2020[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 6-11. doi: 10.3969/j.issn.1000-6621.2021.01.003
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.01.003
[1] |
Moreira-Teixeira L, Tabone O, Graham CM, et al. Mouse transcriptome reveals potential signatures of protection and pathogenesis in human tuberculosis. Nat Immunol, 2020,21(4):464-476. doi: 10.1038/s41590-020-0610-z.
doi: 10.1038/s41590-020-0610-z URL pmid: 32205882 |
[2] | Plumlee CR, Duffy FJ, Gern BH, et al. Ultra-low Dose Aerosol Infection of Mice with Mycobacterium tuberculosis More Closely Models Human Tuberculosis[J/OL]. Cell Host Microbe, 2020[2020-12-14]. doi: 10.1016/j.chom.2020.10.003.Online ahead of print. |
[3] |
Wang L, Wu J, Li J, et al. Host-mediated ubiquitination of a mycobacterial protein suppresses immunity. Nature, 2020,577(7792):682-688. doi: 10.1038/s41586-019-1915-7.
doi: 10.1038/s41586-019-1915-7 URL pmid: 31942069 |
[4] |
Huang H, Wang C, Rubelt F, et al. Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening. Nat Biotechnol, 2020,38(10):1194-1202. doi: 10.1038/s41587-020-0505-4.
doi: 10.1038/s41587-020-0505-4 URL pmid: 32341563 |
[5] |
Khan N, Downey J, Sanz J, et al. M.tuberculosis Reprograms Hematopoietic Stem Cells to Limit Myelopoiesis and Impair Trained Immunity. Cell, 2020, 183(3): 752-770.e22. doi: 10.1016/j.cell.2020.09.062.
doi: 10.1016/j.cell.2020.09.062 URL pmid: 33125891 |
[6] |
Ji DX, Yamashiro LH, Chen KJ, et al. Type Ⅰ interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. Nat Microbiol, 2019,4(12):2128-2135. doi: 10.1038/s41564-019-0578-3.
doi: 10.1038/s41564-019-0578-3 URL pmid: 31611644 |
[7] |
Scheuermann L, Pei G, Domaszewska T, et al. Platelets Restrict the Oxidative Burst in Phagocytes and Facilitate Primary Progressive Tuberculosis. Am J Respir Crit Care Med, 2020,202(5):730-744. doi: 10.1164/rccm.201910-2063OC.
doi: 10.1164/rccm.201910-2063OC URL pmid: 32421376 |
[8] |
Wang Q, Boshoff HIM, Harrison JR, et al. PE/PPE proteins mediate nutrient transport across the outer membrane of Mycobacterium tuberculosis. Science, 2020,367(6482):1147-1151. doi: 10.1126/science.aav5912.
doi: 10.1126/science.aav5912 URL pmid: 32139546 |
[9] |
Rempel S, Gati C, Nijland M, et al. A mycobacterial ABC transporter mediates the uptake of hydrophilic compounds. Nature, 2020,580(7803):409-412. doi: 10.1038/s41586-020-2072-8.
doi: 10.1038/s41586-020-2072-8 URL |
[10] |
Zhang L, Zhao Y, Gao Y, et al. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol. Science, 2020,368:1211-1219. doi: 10.1126/science.aba9102.
doi: 10.1126/science.aba9102 URL pmid: 32327601 |
[11] | Guo H, Courbon GM, Bueler SA, et al. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bed-aquiline[J/OL]. Nature, 2020[2020-12-14]. doi: 10.1038/s41586-020-3004-3. Online ahead of print. |
[12] |
Gupta RK, Turner CT, Venturini C, et al. Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet Respir Med, 2020,8(4):395-406. doi: 10.1016/s2213-2600(19)30282-6.
doi: 10.1016/S2213-2600(19)30282-6 URL pmid: 31958400 |
[13] |
Turner CT, Gupta RK, Tsaliki E, et al. Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study. Lancet Respir Med, 2020,8(4):407-419. doi: 10.1016/s2213-2600(19)30469-2.
doi: 10.1016/S2213-2600(19)30469-2 URL pmid: 32178775 |
[14] |
Ahmad R, Xie L, Pyle M, et al. A rapid triage test for active pulmonary tuberculosis in adult patients with persistent cough. Sci Transl Med, 2019, 11(515): eaaw8287. doi:10.1126/scitranslmed.aaw8287.
doi: 10.1126/scitranslmed.aaw8287 URL pmid: 31645455 |
[15] |
Eloi P, Nascimento GA, Córdula C, et al. Toward a point-of-care diagnostic for specific detection of Mycobacterium tuberculosis from sputum samples. Tuberculosis (Edinb), 2020,121:101919. doi: 10.1016/j.tube.2020.101919.
doi: 10.1016/j.tube.2020.101919 URL |
[16] |
Mishra H, Reeve BWP, Palmer Z, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. The Lancet Respiratory Medicine, 2020,8:368-382. doi: 10.1016/s2213-2600(19)30370-4.
doi: 10.1016/S2213-2600(19)30370-4 URL pmid: 32066534 |
[17] | Feuerriegel S, Kohl TA, Utpatel C, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex®-MycTB[J/OL]. Eur Respir J, 2020[2020-12-14]. doi: 1183/13993003.01796-2020. |
[18] |
Divala TH, Fielding KL, Kandulu C, et al. Utility of broad-spectrum antibiotics for diagnosing pulmonary tuberculosis in adults: a systematic review and meta-analysis. Lancet Infect Dis, 2020,20(9):1089-1098. doi: 10.1016/s1473-3099(20)30143-2.
doi: 10.1016/S1473-3099(20)30143-2 URL pmid: 32437700 |
[19] |
Ouchi Y, Mukai T, Koide K, et al. WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resis-tant Mycobacterium tuberculosis. Tuberculosis (Edinb), 2020,120:101891. doi: 10.1016/j.tube.2019.101891.
doi: 10.1016/j.tube.2019.101891 URL |
[20] |
de Jager VR, Dawson R, van Niekerk C, et al. Telacebec (Q203), a New Antituberculosis Agent. N Engl J Med, 2020,382(13):1280-1281. doi: 10.1056/NEJMc1913327.
doi: 10.1056/NEJMc1913327 URL pmid: 32212527 |
[21] |
Abidi S, Achar J, Assao Neino MM, et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J, 2020,55(3):1901467. doi: 10.1183/13993003.01467-2019.
doi: 10.1183/13993003.01467-2019 URL pmid: 31862767 |
[22] |
Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020,382(10):893-902. doi: 10.1056/NEJMoa1901814.
doi: 10.1056/NEJMoa1901814 URL pmid: 32130813 |
[23] | Franke MF, Khan P, Hewison C, et al. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid: A Prospective Multi-country Study[J/OL]. Am J Respir Crit Care Med, 2020[2020-12-14]. doi: 10.1164/rccm.202001-0135OC. Online ahead of print. |
[24] |
Olayanju O, Esmail A, Limberis J, et al. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. Eur Respir J, 2020,55(1):1901181. doi: 10.1183/13993003.01181-2019.
doi: 10.1183/13993003.01181-2019 URL pmid: 31619478 |
[25] |
Blanc FX, Badje AD, Bonnet M, et al. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. N Engl J Med, 2020,382(25):2397-2410. doi: 10.1056/NEJMoa1910708.
doi: 10.1056/NEJMoa1910708 URL pmid: 32558469 |
[26] |
Ordonez AA, Wang H, Magombedze G, et al. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. Nat Med, 2020,26(4):529-534. doi: 10.1038/s41591-020-0770-2.
doi: 10.1038/s41591-020-0770-2 URL pmid: 32066976 |
[27] |
Ravenscroft L, Kettle S, Persian R, et al. Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova. Eur Respir J, 2020,56(2):2000493. doi: 10.1183/13993003.00493-2020.
doi: 10.1183/13993003.00493-2020 URL pmid: 32381495 |
[28] |
Schrager LK, Vekemens J, Drager N, et al. The status of tuberculosis vaccine development. Lancet Infect Dis, 2020,20(3):e28-e37. doi: 10.1016/S1473-3099(19)30625-5.
doi: 10.1016/S1473-3099(19)30625-5 URL pmid: 32014117 |
[29] |
Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med, 2019,381(25):2429-2439. doi: 10.1056/NEJMoa1909953.
doi: 10.1056/NEJMoa1909953 URL pmid: 31661198 |
[30] |
Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature, 2020,577(7788):95-102. doi: 10.1038/s41586-019-1817-8.
doi: 10.1038/s41586-019-1817-8 URL pmid: 31894150 |
[31] |
Gupta RK, Calderwood CJ, Yavlinsky A, et al. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nat Med, 2020,26(12):1941-1949. doi: 10.1038/s41591-020-1076-0.
doi: 10.1038/s41591-020-1076-0 URL pmid: 33077958 |
[32] | World Health Organization. WHO consolidated guidelines on tuberculosis preventive treatment. Geneva: World Health Organization, 2020. |
[33] |
Huang CC, Becerra MC, Calderon R, et al. Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med, 2020,202(8):1159-1168. doi: 10.1164/rccm.201908-1576OC.
doi: 10.1164/rccm.201908-1576OC URL pmid: 32551948 |
[34] |
Ganmaa D, Uyanga B, Zhou X, et al. Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease. N Engl J Med, 2020,383:359-368. doi: 10.1056/NEJMoa1915176.
doi: 10.1056/NEJMoa1915176 URL pmid: 32706534 |
[35] |
Theron G, Limberis J, Venter R, et al. Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis. Nat Med, 2020,26(9):1435-1443. doi: 10.1038/s41591-020-0940-2.
doi: 10.1038/s41591-020-0940-2 URL pmid: 32601338 |
[36] |
Ruhl CR, Pasko BL, Khan HS, et al. Mycobacterium tuberculosis Sulfolipid-1 Activates Nociceptive Neurons and Induces Cough. Cell, 2020, 181(2): 293-305.e11. doi: 10.1016/j.cell.2020.02.026.
doi: 10.1016/j.cell.2020.02.026 URL pmid: 32142653 |
[1] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[2] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[3] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[4] | Zhang Peize, Gao Qian, Deng Guofang. [18F]FDT-PET-CT technology that may bring revolutionary changes to tuberculosis clinical research [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 262-265. |
[5] | Huang Misun, Wu Yaning, Li Guilian, Liu Haican. Research advances of Mycobacterium tuberculosis enrichment technology [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 369-373. |
[6] | Zhang Chao, Yu Xia, Huang Hairong, Liu Wei, Liu Tao. Evaluation of the in vitro antimicrobial effects of sevoflurane on Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 158-163. |
[7] | You Chengdong, Zhu Ling, Li Peibo. Research progress on serum trace elements in the development and nutritional support of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 218-223. |
[8] | Fu Ying, Xiong Yangyang, Fang Si, Li Chuanxiang, Guo Hongrong. The research progress on the relationship between serum albumin and its derivative biomarkers and chronic obstructive pulmonary disease [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 231-236. |
[9] | Liu Ruihua, Sarina , Wang Furong. Interaction between lung cancer and tuberculosis in disease development and progression [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 102-111. |
[10] | Chen Jifei, Huang Lihua, Luo Lanbo, Sui Wenxian, Pang Yu, Liu Aimei. Evaluation the efficacy of tongue swab-based PCR fluorescence probe method for pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 51-60. |
[11] | Lu Hailin, Wang Wenfei, Tao Wenhui, Lin Peicong, Chen Xinchun, Deng Guofang, Xie Shuixiang. Oleic acid upregulates the expression of perilipin 2 enhancing macrophage clearance of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 72-76. |
[12] | Wang Yilin, Wu Xiao, Pang Yu, Li Shanshan. Immunomodulatory effect of orelabrutinib in host macrophages infected with mycobacterium [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1063-1068. |
[13] | Palidanguli Abudureheman, Wang Senlu, Gulina Badeerhan, Wang Le, Zulikatiayi Abudula, Wang Xinqi, Maiwulajiang Yimamu, Wang Xijiang. Distribution of Mycobacterium tuberculosis genotypes in Kashgar region and their association with clinical characteristics of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1077-1082. |
[14] | Li Wenhan, Yang Jing, Li Chunhua. Research progress of artificial intelligence in pulmonary tuberculosis imaging diagnosis and drug resistance prediction [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1098-1103. |
[15] | Xu Chunhua, Zhu Shiyu, Hu Yi, Yi Kehua, Song Canlei, Wang Zichun, Wu Yong, Wang Qing, Yang Qianru, Shen Xin. Analysis of screening effect of recombinant Mycobacterium tuberculosis fusion protein in screening Mycobacterium tuberculosis infection in close contacts of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 897-902. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||